Researchers frequently use chimeric antigen receptor (CAR) T cells, MHC class I‐restricted T cell receptor (TCR), CD8+, CD4+, and bulk T cells to treat patients with cancer.[74] In this section, the outcomes of some of these studies are discussed. The gene discussed is CD8A; the disease is cancer.